ReviewNature reviews. Clinical oncology2026
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons.
Review in Nature reviews. Clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergizing radiotherapy and immunotherapy for locally advanced gastric cancer: evolving paradigms and future directions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The landscape of gastro-oesophageal adenocarcinoma (GEA) management has undergone substantial transformation over the past decade owing to shifts in epidemiology, evolving treatment paradigms and the integration of new therapeutic strategies. The global burden of GEA continues to rise, with differing patterns observed in Asia compared with Western countries. Important insights gleaned from recent high-profile clinical trials - both successful and negative - have considerably reshaped perioperative treatment strategies, redefining the roles of chemotherapy, radiotherapy, immune checkpoint inhibitors and targeted therapies. Although still investigational, organ-preserving approaches and circulating tumour DNA (ctDNA)-based patient stratification are shaping the direction of future GEA management. By consolidating these developments, this Review aims to provide clinicians and researchers with a comprehensive and structured guide to the state-of-the-art perioperative management of GEA, emphasizing the underlying biology, clinical implications and future directions.
Indexed as
Identifiers
42141214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.